Abstract:
Objective Glucorticoid therapy has the potential to mitigate immunogical effect of naxitamab. Ketamine is an anesthetic medication and cause weak or shallow breathing. This article is to analyze the effect of modified conditioning regimen with substitution remifentanil for ketamine and without glucorticoid therapy on adverse events associated with naxitamab.
Methods Clinical data with naxitamab infusion under modified conditioning regimen in Sun Yat-sen University Cancer Center between June 2023 and June 2024 were retrieved to analyze adverse events and risk factors.
Results Overall, seventeen patients underwent 201 infusions. The most frequent adverse events were as follows: neurological pain (all grades) 93.0%, hypertension 55.7%, hypotension 34.8%, respectively. Bronchospasm and hypoxia were seen in 3.0% and 10.9% infusions, respectively. Fever occurred less frequently in the second cycle of infusion. No patients suspended infusion due to severe adverse event.
Conclusions The infusion of naxitamab is tolerable under the modified conditioning regimen and adverse event is less than expected and controllable.
下载: